Amundi Has $19.09 Million Stock Holdings in Baxter International Inc. $BAX

Amundi increased its position in shares of Baxter International Inc. (NYSE:BAX) by 12.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 895,147 shares of the medical instruments supplier’s stock after buying an additional 97,411 shares during the quarter. Amundi’s holdings in Baxter International were worth $19,085,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Basepoint Wealth LLC purchased a new stake in shares of Baxter International during the 4th quarter worth about $26,000. Jones Financial Companies Lllp bought a new stake in shares of Baxter International in the 2nd quarter valued at approximately $26,000. Imprint Wealth LLC acquired a new position in Baxter International in the third quarter worth approximately $27,000. CYBER HORNET ETFs LLC increased its holdings in Baxter International by 52.4% in the second quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 740 shares during the last quarter. Finally, MUFG Securities EMEA plc bought a new position in Baxter International during the second quarter valued at approximately $46,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Down 1.6%

BAX stock opened at $23.80 on Friday. The stock has a market capitalization of $12.31 billion, a price-to-earnings ratio of -11.50, a price-to-earnings-growth ratio of 3.65 and a beta of 0.60. The company has a 50-day moving average of $24.98 and a two-hundred day moving average of $20.84. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities research analysts anticipate that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be given a $0.01 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Analyst Upgrades and Downgrades

BAX has been the subject of several recent research reports. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. TD Cowen raised their price target on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. The Goldman Sachs Group lifted their price objective on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Wall Street Zen raised shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, UBS Group raised their target price on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $22.45.

About Baxter International

Baxter International Inc is a global healthcare company that develops and supplies medical products and technologies used in hospitals, outpatient facilities, physician offices and other care settings. Its offerings include intravenous therapy products and infusion systems, injectable medications and drug-compounding technologies, surgical products, patient-monitoring systems, respiratory-care equipment, and products used in hospital beds and connected-care environments.

The company serves healthcare providers and patients in numerous countries, with operations and customers across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.